You might never have heard about guselkumab, which targets IL-23. Other
MABs targeting IL-23 include briakinumab (nothing at the EULAR 2017 meeting), tildrakizumab
(nothing at the EULAR 2017 meeting), and ustekinumab (already available as
Stelara). To be more specific: guselkumab (GUS) is a fully human monoclonal
antibody (MAB) against the p19 subunit of IL-23.
A. Deodhar and colleagues published [1]: “EFFICACY AND SAFETY RESULTS
OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE
PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED STUDY”. The authors concluded: “In pts with active PsA [psoriatic
arthritis] and ≥3% BSA [Body Surface Area] of
psoriasis, GUS demonstrated significant improvement on joint symptoms, physical
function, psoriasis, enthesitis, dactylitis and quality of life. GUS was well
tolerated with no unexpected safety findings in this population.”
It’s still too early to do projections into the future. A word of
warning however: we had hardly any options to treat psoriatic arthritis for
long time, now we see a proliferation of different principles. Psoriatic
arthritis is less common than rheumatoid arthritis; PsA has a prevalence of
0.16-0.25 % and RA 0.5-1.0 % [2]. Though we are happy for any new therapeutic
principle, we shall have a long way to put all the options into a working
algorithm.
Links and
References:
[1] Annals of the Rheumatic Diseases, volume 76, supplement 2, year
2017, page 142 / Session: PsA: the options grow! , (Oral Presentations ) /
DOI: 10.1136/annrheumdis-2017-eular.1164
.
No comments:
Post a Comment